Arrowhead Pharmaceuticals, Inc.
ARWR
$55.05
$0.040.07%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 117.80% | 86.07% | -2.60% | 395.65% | -30.27% |
| Total Depreciation and Amortization | 22.06% | 27.08% | 30.13% | 34.45% | 22.80% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 31.20% | 274.65% | 24.31% | 51.81% | 34.13% |
| Change in Net Operating Assets | -730.55% | -582.39% | -172.88% | 1,251.69% | 31.57% |
| Cash from Operations | 109.22% | 114.93% | -34.05% | 598.02% | -24.13% |
| Capital Expenditure | 71.42% | 69.17% | 83.64% | 84.45% | 89.05% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -125.58% | 140.33% | 571.81% | -76.66% | -36.76% |
| Cash from Investing | -130.87% | 132.58% | 1,934.68% | -56.25% | 18.62% |
| Total Debt Issued | -- | -99.19% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 8,090.85% | 127.35% | -42.38% | -43.36% | 137.45% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -100.00% | -- | -- |
| Cash from Financing | -171.48% | -99.06% | -184.70% | -78.55% | 7,628.09% |
| Foreign Exchange rate Adjustments | 255.88% | -100.55% | 141.70% | -1,646.15% | -217.24% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 48.96% | 190.68% | 4.10% | 89.70% | 7.37% |